Mabpharm Limited — Capital/Financing Update 2021

Jun 29, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [73 x 86] intentionally omitted <==

Mabpharm Limited 邁博葯業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2181)

VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH SHANDONG KEXING BIOPRODUCTS CO., LTD IN RELATION TO CMAB008

This announcement is made by Mabpharm Limited (the “ Company ”, together with its subsidiaries, the “ Group ”), on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

EXCLUSIVE LICENSE AGREEMENT WITH KEXING BIOPRODUCTS

On June 28, 2021, Taizhou Mabtech Pharmaceutical Limited* (泰州邁博太科藥業有限公司) (“ Taizhou Pharmaceutical ”), an indirect wholly-owned subsidiary of the Company, entered into an exclusive license agreement with Shandong Kexing Bioproducts Co., Ltd* (科興生物製藥股份有限公司) (“ Kexing Bioproducts ”), a company listed on the Science and Technology Innovation Board of Shanghai Stock Exchange (stock code: 688136), pursuant to which Taizhou Pharmaceutical has granted Kexing Bioproducts an exclusive license for the development and commercialization of CMAB008 in all countries and regions other than Mainland China, Japan, Europe and North America (the “ Cooperative Regions ”). The term of the exclusive license in respect of each Cooperative Region shall be counted separately, and shall be not less than 10 years (which may be automatically extended for another 10 years) from the date CMAB008 obtains approval for marketing in such Cooperative Region. Taizhou Pharmaceutical has reached an agreement with Kexing Bioproducts on the sales targets for countries and regions in the Americas (other than North America): not less than 200,000 units in aggregate for the first and second full sales years and not less than 200,000 units/year commencing from the third full sales year.

CMAB008 is a recombinant anti-TNF-alpha chimeric monoclonal antibody, a biosimilar of infliximab for rheumatoid arthritis, adult and pediatric patients with Crohn’s disease, fistulizing Crohn’s disease, ankylosing spondylitis, psoriasis and adult patients with ulcerative colitis, and one of the core products of the Group. For further details of CMAB008, please refer to the 2020 annual report of the Company.

– 1 –

ABOUT KEXING BIOPRODUCTS

Kexing Bioproducts is an innovative biopharmaceutical enterprise mainly engaged in the research and development, production and sales of recombinant protein therapeutics and microbiota agents, focusing on pharmaceutical research in the therapeutic fields of antiviral, tumor and immunological, hematological, digestive and degenerative diseases.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain approval, develop or ultimately market, CMAB008 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board Mabpharm Limited Jiao Shuge Chairman

Hong Kong, June 29, 2021

As at the date of this announcement, the Board of Directors comprises Dr. Wang Hao, Mr. Tao Jing, Mr. Li Yunfeng, and Dr. Li Jing as executive Directors; Mr. Jiao Shuge and Mr. Guo Jianjun as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun and Dr. Liu Linqing as independent non-executive Directors.

• For identification purpose only

– 2 –